EMPOWER-Lung 3

Episode
134
Soundcloud
Share

This episode of Lung Cancer Considered is part of our series on FDA approvals of new lung cancer therapies. Today, host Dr. Stephen Liu discusses the EMPOWER-Lung 3 regimen of the PD-1 inhibitor cemiplimab with first-line platinum doublet chemotherapy for advanced NSCLC. This regimen was approved by the FDA on November 8, 2022.

His guests are Dr. Jordi Remon, a thoracic medical oncologist who had previously practiced at Hospital de Mataro in Barcelona. He is now part of the esteemed thoracic unit at Gustave Roussy in Paris and the secretary of the Lung Cancer Group of EORTC. Joining Dr. Remon is Dr. Isabel Preeshagul, a thoracic medical oncologist and Assistant Attending with Memorial Sloan Kettering. She is also the chair of the Education and Engagement Committee of the Lung Cancer Research Foundation.

Guest
Stephen Liu, MD
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Isabel Preeshagul
Isabel Preeshagul

MD

Thoracic Medical Oncologist
Memorial Sloan Kettering
Jordi-Remon
Jordi Remon

MD, PhD

Medical Oncologist
Gustave Roussy

Other Podcast

Lung Cancer in Brazil
Episode
141
Patient Advocacy Groups Podcast
Episode
140
Radon Podcast
Episode
139
FDA Approval: Adagrasib
Episode
138